LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\)

Clinical trials for LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\) explained in plain language.

Never miss a new study

Get alerted when new LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\) trials appear

Sign up with your email to follow new studies for LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New study tracks toddlers with rare muscle disease to pave way for future treatments

Knowledge-focused Recruiting now

This study watches how children aged 0 to 5 with LAMA2-related muscular dystrophy move and develop over two years. Researchers will test muscle function, swallowing, breathing, and collect blood samples. The goal is to learn more about the disease and prepare for future treatment…

Matched conditions: LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\)

Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused

Last updated May 17, 2026 10:26 UTC

LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\)

Get alerted when new LAMA2-MD \(MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A\) trials appear

New study tracks toddlers with rare muscle disease to pave way for future treatments